ScreenerHero

IMRXImmuneering Corporation Class A Common Stock

NAS · US · Healthcare · Biotechnology · immuneering.com
5.300USD-0.56%Mkt Cap: 342.90M $P/E: —

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a P…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap342.90M $
Enterprise Value193.39M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-56.02M $
Revenue/Share—
Last Price5.300 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees57
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.07
PEG—
EV/EBITDA-3.06
EV/Revenue—
P/S—
P/B1.78
EPS (TTM)-0.92
EPS (Forward)-1.29
52W Range
3.25030% of range10.08
52W High10.08 USD
52W Low3.250 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-25.64%
ROA-24.15%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-45.34M $
CapEx (TTM)142.23K $
FCF Margin—
FCF Yield-11.48%
Net Debt-146.27M $
Net Debt/EBITDA2.32
Balance Sheet
Debt/Equity0.02
Current Ratio19.47
Quick Ratio18.47
Book Value/Sh2.948 USD
Cash/Share2.317 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)18.25 USD
Upside (mean)+244.3%
Target Range12.00 USD – 30.00 USD
$12.00+244.3% to mean$30.00
# Analysts8
Ownership
Shares Out.64.70M
Float49.21M
Insiders13.82%
Institutions55.64%
Short Interest
Short Ratio17.9d
Short % Float31.37%
Short % Out.23.81%
Shares Short15.40M
Short (prev mo.)15.03M
Technical
SMA 504.681 (+13.2%)
SMA 2005.343 (-0.8%)
Beta0.37
S&P 52W Chg18.16%
Avg Vol (30d)724.67K
Avg Vol (10d)722.83K
Technical Indicators
RSI (14)65.9
MACD0.1679
MACD Signal0.0557
MACD Hist.+0.1122
BB Upper5.467 USD
BB Middle4.608 USD
BB Lower3.749 USD
BB Width37.28%
ATR (14)0.2512 USD
Vol Ratio (20d)0.68x